Brief: Jcr Pharmaceuticals Receives Orphan Drug Designation For Givinostat In Japan
28/09/2026 18:11
BRIEF-Jcr Pharmaceuticals Receives Orphan Drug Designation For Givinostat In Japan Sept 28 (Reuters) - JCR Pharmaceuticals Co., Ltd. 4552.T:
JCR PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FROM THE MINISTRY OF HEALTH, LABOUR AND WELFARE OF JAPAN FOR GIVINOSTAT FOR DUCHENNE MUSCULAR DYSTROPHY
JCR PHARMACEUTICALS CO., - TO SUBMIT MARKETING AUTHORIZATION APPLICATION FOR GIVINOSTAT IN JAPAN BY END 2026
Source text: ID:nBwc8mj60a
Further company coverage: 4552.T
((((Reuters.Briefs@thomsonreuters.com));))
Recent news on JCR Pharmaceuticals
See all newsBrief: JCR Pharmaceuticals Receives Marketing Authorization In Kuwait For Izcargo
Italfarmaco And Jcr Pharmaceuticals Enter Into Exclusive License Agreement For Jr-141 In United States, Europe, And Latin America
Brief: Jcr Pharmaceuticals Receives Orphan Drug Designation For Givinostat In Japan
Brief: Medipal & JCR Dose First Patient In Global Phase I/II Trial OF JR-446 For Mucopolysaccharidosis Type IIIB
Table: Jcr Pharmaceuticals -Q1 group results